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Changes in the Demographics and Prognoses of Patients with 
Resected Non-Small Cell Lung Cancer: A 20-Year Experience at  
a Single Institution in Korea
The demographics and prognosis of non-small cell lung cancer patients have changed 
during the last few decades. We conducted this study to assess the change in 
demographics and prognosis in resected non-small cell lung cancer patients during a 20-yr 
single-institution study in Korea. We retrospectively reviewed the medical records of 2,076 
non-small cell lung cancer patients who underwent pulmonary resection between 1990 
and 2009. Their clinical characteristics and survival were analyzed over a five-year period. 
With time, the proportions of female, adenocarcinoma, stage IA, and lobectomy patients 
increased, whereas the proportions of male, squamous cell carcinoma, stage IIIA, and 
pneumonectomy patients decreased. These demographic changes caused improved 
prognosis. The five-year survival rate of all patients was 53.9%. The five-year survival rate 
increased from 31.9% in 1990-1994, to 43.6% in 1995-1999, 51.3% in 2000-2004, and 
69.7% in 2005-2009 (P < 0.001). In conclusion, among patients with resected non-small 
cell lung cancer, the proportions of female, adenocarcinoma, stage IA, and lobectomy 
patients have increased, and the five-year survival rate has gradually improved during the 
last 20 yr in Korea. 
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INTRODUCTION
Lung cancer is the leading cause of cancer deaths in the West-
ern world as well as in Korea (1-3). Non-small cell lung cancer 
(NSCLC) constitutes more than 80% of lung cancer cases, and 
surgery remains the only potentially curative treatment for early 
stage lung cancer. During the last few decades, the clinical pro-
file of NSCLC patients who are candidates for surgical resection 
has changed dramatically. According to the Japanese Joint Com-
mittee for Lung Cancer Registration (JJCLCR), the proportions 
of patients who are female, have stage IA disease, and have ad-
enocarcinoma have increased, and the five-year survival rate 
has gradually improved from 47.2% in 1989, to 52.6% in 1994, to 
61.4% in 1999, and to 69.6% in 2004 (4-7). As such, it is important 
to understand the demographics, tumor-related background, 
and the prognosis by related factors and stage. In addition, de-
termining trends in those parameters will be helpful in devel-
oping nation-specific strategies for lung cancer treatment. In 
this study, we analyzed 20 yr of single-institution data to identify 
the recent surgical outcomes and trends related to non-small 
cell lung cancer surgery in Korea. 
MATERIALS AND METHODS
Patients
We reviewed the records of 2,076 patients with NSCLC who 
underwent pulmonary resection at our institute from January 
1990 to December 2009. Pathological staging was based on the 
2009 TNM classification system (8). Tumor histology was cate-
gorized according to the World Health Organization classifica-
tion. Lymph node status was assessed according to the system 
defined by Mountain and Dresler (9). Lobectomy and system-
atic lymph node dissection were the procedures of choice, re-
gardless of clinical stage. Patients with stage I-IIIA disease were 
indicated for surgical resection. All patients were followed either 
until death or the last follow-up date (December 1, 2011). 
Statistical analysis
The duration of survival was defined as the interval between 
the date of surgery and either the date of death or the last fol-
low-up date. Survival curves were estimated using the Kaplan-
Meier method, and differences in survival were assessed by the 
log-rank test. In the analysis of pathologic stage and survival, 
the patients (n = 169) who received induction treatment were 
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excluded. A P  value less than 0.05 was considered significant. 
The data were analyzed using SPSS for Windows (Statistical Pack-
age for the Social Sciences, SPSS Inc. Chicago, IL, USA).
Ethics statement
The institutional review board of Yonsei University College of 
Medicine approved this retrospective study (4-2012-0505). In-
formed consent was waived by the board.
RESULTS
Patient characteristics
The 2,076 patients included 558 females and 1,518 males with a 
median age of 62 yr (range, 10 to 90 yr). The median follow-up 
Table 1. Clinical and pathologic characteristics of 2,076 patients
Parameters No. of patients (%)
Age (median, range) 62.0 (10-90)
Sex
   Male
   Female
 
1,518 (73.1)
558 (26.9)
Type of resection
   Pneumonectomy
   Bilobectomy
   Lobectomy
   Other
 
559 (26.9)
229 (11.0)
1,234 (59.4)
54 (2.6)
Histologic subtype
   Squamous cell carcinoma
   Adenocarcinoma
   Large cell
   Other
 
902 (43.4)
923 (44.5)
89 (4.3)
162 (7.8)
Pathologic stage
   IA
   IB
   IIA
   IIB
   IIIA
   IIIB
   IV
 
358 (18.8)
441 (23.1)
289 (15.2)
207 (10.9)
503 (26.4)
65 (3.4)
44 (2.3)
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Fig. 1. Number of NSCLC patients with resection, adenocarcinoma and stage I ac-
cording to time. The proportion of patients with pathologic stage I disease and adeno-
carcinoma increased from 16.6% (5/30) and 33.3% (10/30), respectively, in 1990 to 
58.2% (131/225) and 64.0% (144/225), respectively, in 2009 (NSCLC: non-small 
cell lung cancer).
Table 2. Proportion of cases according to time period
Parameters 1990-1994 1995-1999 2000-2004 2005-2009
No. of patients 260 415 523 878
Age (yr, mean ± SD) 57.8 ± 9.0 59.7 ± 9.7 60.7 ± 10.1 62.5 ± 10.0
Sex
   Male
   Female
 
214 (82.3%)
  46 (17.7%)
 
328 (79.0%)
  87 (21.0%)
 
389 (74.4%)
134 (25.6%)
 
587 (66.9%)
291 (33.1%)
Histology
   Squamous
   Adenocarcinoma
   Other
 
151 (58.1%)
  77 (29.6%)
  32 (12.3%)
 
210 (50.6%)
151 (36.4%)
  54 (13.0%)
 
233 (44.6%)
211 (40.4%)
  79 (15.0%)
 
308 (35.1%)
484 (55.1%)
86 (9.8%)
Procedure
   Pneumonectomy
   Bilobectomy
   Lobectomy
   Other
 
152 (58.5%)
21 (8.1%)
  78 (30.0%)
  9 (3.5%)
 
205 (49.4%)
  66 (15.9%)
136 (32.7%)
13 (3.1%)
 
133 (25.4%)
  61 (11.7%)
314 (60.0%)
15 (2.9%)
 
69 (7.9%)
81 (9.2%)
706 (80.5%)
22 (2.5%)
pStage
   IA
   IB
   IIA
   IIB
   IIIA
   IIIB
   IV
 
14 (6.0%)
  40 (17.0%)
  44 (18.7%)
  27 (11.5%)
  92 (39.1%)
14 (6.0%)
  4 (1.7%)
 
  41 (10.6%)
  76 (19.6%)
  53 (13.7%)
  47 (12.1%)
136 (35.1%)
21 (5.4%)
14 (3.6%)
 
  68 (14.6%)
123 (26.4%)
  74 (15.9%)
  52 (11.2%)
117 (25.1%)
17 (3.6%)
15 (3.2%)
 
235 (28.7%)
202 (24.7%)
118 (14.4%)
81 (9.9%)
158 (19.3%)
13 (1.6%)
11 (1.3%)
Tumor size (cm) 4.5 ± 2.5 4.2 ± 2.2 3.8 ± 2.2 3.4 ± 2.0
Smoking History
   Yes
   No
 
150 (57.7%)
110 (42.3%)
 
263 (63.4%)
152 (36.6%)
 
294 (56.2%)
229 (43.8%)
 
460 (52.4%)
418 (47.6%)
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time was 37.3 months (range, 0 to 261.9 months). All patient 
characteristics are summarized in Table 1. The overall five-year 
survival rate was 53.9%. The five-year survival rate was 85.6% 
for stage IA, 71.7% for IB, 48.4% for IIA, 46.2% for IIB, 33.1% for 
IIIA, 5.2% for stage IIIB, and 17.1% for stage IV.
Trends in characteristics
In the time period from 1990 to 2009, the proportion of patients 
with pathologic stage I disease increased from 16.6% (5/30) in 
1990 to 58.2% (131/225) in 2009. In terms of lung cancer sub-
type, the proportion of adenocarcinomas increased annually 
from 33.3% (10/30) in 1990 to 64.0% (144/225) in 2009 (Fig. 1), 
while the proportion of squamous cell carcinomas decreased 
annually from 56.6% (17/30) in 1990 to 30.2% (68/225) in 2009. 
This shift in the distribution of tumor subtypes was prominent 
after the mid-2000s.
 Patients were divided into the following four groups based 
on their year of surgery: 1990-1994, 1995-1999, 2000-2004, and 
2005-2009. The mean age of the patients at the time of the oper-
ation increased over time. The proportions of female, adenocar-
cinoma, lobectomy, and pathologic stage Ia patients increased. 
The proportions of male, squamous histology, pneumonecto-
my and stage IIIa patients decreased over time (Table 2). 
Trends in survival
The overall five-year survival rate of all patients was 53.9%. The 
overall survival rate improved over time, increasing from 31.9% 
in 1990-1994, to 43.6% in 1995-1999, to 51.3% in 2000-2004, and 
to 69.7% in 2005-2009 (P < 0.001, Fig. 2). This tendency was 
similar for every pathologic stage. The five-year survival rate 
increased from 85.7% in 1990-1995 to 89.2% in 2005-2009 for 
stage IA, from 57.5% to 83.6% for stage IB, from 25.0% to 55.3% 
for stage IIA, from 48.1% to 49.5% for stage IIB, from 16.3% to 
53.9% for stage IIIA, from 7.1% to 11.5% for IIIB, and from 0% to 
32.7% for stage IV (Table 3).
DISCUSSION
The demographics and prognoses of non-small cell lung cancer 
patients undergoing surgery at a single Korean institution have 
changed over the last 20 yr. The proportions of patients who are 
female, underwent lobectomy, have stage IA disease, and have 
adenocarcinoma have increased, and the five-year survival rate 
has gradually improved from 31.9% in 1990-1994 to 43.6% in 
1995-1999, to 51.3% in 2000-2004, and to 69.7% in 2005-2009.
 The lung cancer incidence in Western countries (North Amer-
ica, Western Europe, Australia) has stabilized over the past de-
cades (10). However, there have been major shifts in the frequen-
cies of the various histological types of lung cancer, with signifi-
cant increases in the incidence of adenocarcinoma, and a cor-
responding decrease in the incidence of squamous cell cancer. 
For example, registry data from the USA indicated that the ratio 
of squamous carcinomas to adenocarcinomas was approximate-
ly 17:1, and by 1995 these two histological types of cancer were 
nearly equal in incidence. Although lung cancer data are not 
extensively available for Asian populations, the same pattern of 
change has been observed (11). In Taiwan, a study of over 10,000 
cases over the period from 1970 to 1993 showed that the inci-
dence of squamous carcinoma decreased from 46.4% to 36.2% 
in men, whereas adenocarcinoma increased from 30% to 36% 
in men and from 50.7% to 64.8% in women, such that adeno-
carcinoma has now become the most common cancer cell type 
(12). Similar patterns were found in Singapore, Korea, Hong 
Kong and Japan (13-16). This study also showed a similar pat-
tern with surgically resected lung cancer cases and this shift in 
the distribution of cancer types was prominent after the mid-
2000s (Fig. 1).
 The prognosis of surgical resection of NSCLC was not prom-
ising. Despite “curative resection,” more than 70% of patients 
with NSCLC in one study experienced recurrence (17). The five-
Table 3. Five-year survival according to time period
Pathological stage 1990-1994 1995-1999 2000-2004 2005-2009
Overall 31.9% 43.6% 51.3% 69.7%
Sub-stage
   IA
   IB
   IIA
   IIB
   IIIA
   IIIB
   IV
 
85.7%
57.5%
25.0%
48.1%
16.3%
7.0%
0%
 
78.0%
71.1%
50.9%
36.2%
28.7%
0%
0%
 
80.9%
65.0%
52.7%
48.1%
29.9%
5.9%
26.7%
 
89.2%
83.6%
55.3%
49.5%
53.9%
11.5%
32.7%
Stage
   I
   II
   III
   IV
 
64.8%
33.8%
15.1%
0%
 
73.5%
44.0%
24.8%
0%
 
70.7%
50.8%
26.9%
26.7%
 
86.5%
53.0%
50.7%
32.7%
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Fig. 2. Postoperative overall survival curves for patients according to time period. The 
five-year survival rate improved over the 20-yr study period and there were significant 
differences among the groups (P < 0.001) (5YSR: Five-year survival rate). 
2005-2009 (5YSR = 69.7%)
1995-1999 (5YSR = 43.6%)
2000-2004 (5YSR = 51.3%)
1990-1994 (5YSR = 31.9%)
P < 0.001
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year survival rate after resection was 42.6% according to Naruke 
et al. (18) and 41.4% according to van Rens et al. (19). However, 
it is not surprising that postoperative survival is changing with 
each decade based on the date of resection, histology, and the 
distribution of stages. 
 There have been a few reports focusing on the change in sur-
gical results over time (Table 4). Koike et al. (20) divided the 
dates of resection into three periods and reported that the pro-
portion of stage IA cases increased and that the five-year sur-
vival rate improved over time (33.7% in 1963-1977, 51.8% in 
1978-1986, and 58.4% in 1987-1992). Fang and coworkers (21) 
compared the NSCLC surgical results from four periods: 1960s, 
1970s, 1980s, and 1990s. They reported that the five-year surviv-
al rate improved with some influencing factors, such as the rate 
of postoperative complications, lymph node dissection, and 
combination therapy. Yoshino and coworkers (22) compared 
the surgical results for NSCLC resected in the three decades from 
1975 to 1998 and reported that the five-year survival rates im-
proved (30.3% in the 1970s, 41.6% in the 1980s, and 50.1% in the 
1990s) due to an increasing number of female patients with ad-
enocarcinoma, more frequent detection of early disease, and 
effective elimination of unresectable cases. 
 The Japanese Joint Committee for Lung Cancer Registration 
(JJCLCR) reported that the proportions of patients who are fe-
male, have stage IA disease, and have adenocarcinoma have 
increased, and the five-year survival rate has gradually improved, 
from 47.2% in 1989, to 52.6% in 1994, to 61.4% in 1999, and to 
69.6% in 2004 (4-7). In this study, the postoperative five-year sur-
vival rate in Korea improved from 31.9% in 1990-1994, to 43.6% 
in 1995-1999, to 51.3% in 2000-2004, and to 69.7% in 2005-2009, 
mainly due to increased proportions of female patients, patho-
logic stage IA cases and decreased pneunonectomy cases. The 
prognosis for this surgical result is similar to that in the JJCLCR 
reports, and has changed more dramatically due to the promi-
nent change in demographics after the mid-2000s. The recent 
favorable surgical outcomes including those presented by the 
JJCLCR and in this report suggest that good surgical results for 
NSCLC have been achieved. 
 With regard to the change in the five-year survival rate accord-
ing to sub-staging groups, the data are not sufficient to fully eval-
uate the prognosis of all stages in each period due to the rela-
tively small number of cases from our single institution. How-
ever, the trend of improvement in survival rate was noted in all 
subgroups. This improvement in each stage is likely due to a 
decreased mean tumor size (from 4.5 cm in 1990-1994 to 3.4 cm 
in 2005-2009), decreased proportion of pneumonectomy cases, 
standardization of adjuvant chemotherapy, increased propor-
tion of female patients, and increased proportion of adenocar-
cinoma, which is a good target for recently developed chemo-
therapy. 
 To the best of our knowledge, this is the first report from Ko-
rea assessing the recent trends in demographics and prognoses 
for resected NSCLC cases. In conclusion, the clinical profiles of 
resected non-small cell lung cancer have changed in the last 20 
years in Korea. The proportions of female, stage IA, lobectomy, 
and adenocarcinoma patients have increased, and the five-year 
survival rate has gradually improved from 31.9% in 1990-1994, 
to 43.6% in 1995-1999, to 51.3% in 2000-2004, and to 69.7% in 
2005-2009.
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